These unexpected results led us to investigate whether the blockade of EZH2 may lead to the activation of alternative oncogenic pathways, such as FLT3 and its downstream signaling, previously reported for childhood leukemia [38]. This evidence concerns the gene FLT3 and childhood leukemia.